SCHEMBL7003872

SCHEMBL7003872

O=C1CN(C(=O)O)c2ccccc21

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.73
KCNN4 O15554 2/20 0.53
KCNA3 P22001 2/20 0.53
LMNA P02545 2/20 0.51
RAB9A P51151 2/20 0.51
HTT P42858 2/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 2/20 0.42
CYP3A4 P08684 1/20 0.42
MAPT P10636 1/20 0.42
PABPC1 P11940 1/20 0.42
BLM P54132 1/20 0.42
TSHR P16473 2/20 0.38
USP2 O75604 1/20 0.38
TP53 P04637 1/20 0.38
CES1 P23141 1/20 0.37
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3030097 0.89 NOTUM (0.59) NOTUMKCNN4KCNA3LMNARAB9A
SCHEMBL30003296 0.85 NOTUM (1.00) NOTUMKCNN4KCNA3LMNARAB9A
SCHEMBL1048074 0.85 NOTUM (1.00) NOTUMKCNN4KCNA3LMNARAB9A
SCHEMBL68111 0.84 KCNN4 (0.68) NOTUMKCNN4KCNA3LMNARAB9A
SCHEMBL28021992 0.81 LMNA (0.68) NOTUMLMNARAB9AHTTMEN1
SCHEMBL29634379 0.79 SMN1; SMN2 (0.51) NOTUMKCNN4KCNA3LMNARAB9A
SCHEMBL5711999 0.79 NOTUM (0.70) NOTUMKCNN4KCNA3LMNARAB9A
SCHEMBL3037573 0.78 KCNN4 (0.78) NOTUMKCNN4KCNA3LMNARAB9A
SCHEMBL30667212 0.75 NOTUM (0.64) NOTUMKCNN4KCNA3LMNARAB9A
SCHEMBL7004709 0.75 NOTUM (0.64) NOTUMKCNN4KCNA3LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030105118-A1 Tricyclic quinazolinediones SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-06-05 US disclosed
EP-1288216-A1 TRICYCLIC QUINAZOLINEDIONES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-03-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105118-A1 Tricyclic quinazolinediones PARP1, PARP11, PARP2 NOTUM 4410/4885KCNN4 1557/4885KCNA3 3007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.